Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 583751, 6 pages
Clinical Study

Central Precocious Puberty: Treatment with Triptorelin 11.25 mg

1Adolescent Medicine, I Pediatric Division, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy
2Department of Gynecology, Obstetrics and Pediatrics, University of Bologna, 40138 Bologna, Italy
3Department of Pediatrics, University of Messina, 98124 Messina, Italy
4Department of Paediatrics, University of Florence, 50100 Florence, Italy
5Paediatric Endocrinology, Regina Margherita Children's Hospital, 10126 Turin, Italy
6Endocrinology Unit, Department University-Hospital, Bambino Gesù Children's Hospital, Tor Vergata University, 00165 Rome, Italy
7Pediatric and Adolescent Endocrinology, Department of Pediatrics, San Raffaele Scientific Institute, Vita-Salute S. Raffaele University, 20132 Milan, Italy

Received 9 October 2011; Accepted 22 December 2011

Academic Editor: Thomas E. Adrian

Copyright © 2012 Elena Chiocca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Few data are available on quarterly 11.25 mg GnRH analog treatment in central precocious puberty (CPP). Aim. To assess the efficacy of triptorelin 11.25 mg in children with CPP. Patients. 17 patients (16 females) with CPP ( 7 . 9 ± 0 . 9 years) were treated with triptorelin 11.25 mg/90 days. Methods. Gonadotropins, basal-, and GnRH-stimulated peak, gonadal steroids, and pubertal signs were assessed at preinclusion and at inclusion visit, 3 months, 6 months, and 12 months of treatment. Results. At 3, 6, and 12 months, all patients had suppressed LH peak (<3 IU/L after GnRH stimulation), as well as prepubertal oestradiol levels. Mean LH peak values after GnRH test significantly decreased from 2 5 . 7 ± 1 6 . 5  IU/L at baseline to 0 . 9 ± 0 . 5  IU/L at M3 ( 𝑃 < 0 . 0 0 0 1 ); they did not significantly changed at M6 and M12. Conclusions. Triptorelin 11.25 mg/90 days efficiently suppressed the pituitary-gonadal axis in children with CPP from first administration.